Plain-English translation of NCT03594760 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new imaging scan called PSMA-PET that uses a radioactive tracer called [18F]DCFPyL to find prostate cancer that may have spread to other parts of the body. The scan is designed to be more sensitive than standard imaging tests (like CT scans and bone scans) at finding cancer early. Researchers also want to use artificial intelligence to analyze the scan images and better predict how the cancer might respond to treatment.
Currently, standard imaging tests often miss prostate cancer that has spread, which makes it harder for doctors to plan the best treatment. This new imaging approach has shown promise in detecting cancer earlier and more accurately, and this study aims to confirm those benefits and develop computer tools to make the scans even more useful in predicting treatment outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of a radioactive tracer through your vein, then undergo a PET-CT imaging scan that detects where the tracer collects in your body—showing where prostate cancer may be present. The scan itself typically takes 30–60 minutes, and you'll lie still on a scanning table while the machine takes detailed pictures. Your images will then be analyzed both by radiologists and artificial intelligence to help predict how your cancer might respond to treatment.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Canada
Phase
Large-scale testing
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Enrollment target
~1,000 participants
Started
December 2018
Primary completion
December 2028
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Daniel Juneau, MD
Centre hospitalier de l'Université de Montréal (CHUM)
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.